Leonel Fabrizio Trivisonno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leonel Fabrizio Trivisonno has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Juan Victor Ariel Franco
Cochrane Evidence Synthesis Germany/UK, Düsseldorf Subunit, Institute of General Practice, Centre for Health and Society; Medical Faculty of the Heinrich-Heine-University Düsseldorf; Düsseldorf Germany
4 shared publications - Benjamin Barnes
Zentrum für Krebsregisterdaten (ZfKD), Robert Koch-Institut, Berlin, Deutschland
2 shared publications - Camila Micaela Escobar Liquitay
Research Department, Instituto Universitario Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
2 shared publications - Cecilia Fieiras
Instituto Universitario Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
2 shared publications - Christa Scheidt-Nave
Robert Koch Institute, Berlin, Germany
2 shared publications - Denise Ducks
Department of Epidemiology and Health Monitoring, Robert Koch-Institute, 13353 Berlin, Germany
2 shared publications
Latest Publications
- Open Access
- 1 January 2024
- Published by XMLink in The World Journal of Men's Health
- Vol. 42 (3) , 518-530
Serenoa repens for the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Enlargement: An Updated Cochrane Review
Franco JV, et al. World J Mens Health. 2024 Jan;42:e11. https://doi.org/10.5534/wjmh.230222
- 1 January 2024
- Published by XMLink in The World Journal of Men's Health
- Vol. 42 (3) , 518-530
Open AccessSerenoa repens for the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Enlargement: An Updated Cochrane Review
Franco JV, et al. World J Mens Health. 2024 Jan;42:e11. https://doi.org/10.5534/wjmh.230222
- Open Access
- 3 November 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (21) , 14392
Short and Long-Term Wellbeing of Children following SARS-CoV-2 Infection: A Systematic Review
Post-COVID conditions in children and adolescents were mostly investigated as the incidence of individual or clusters of symptoms. We aimed to describe the findings of studies assessing key outcomes related to global wellbeing and recovery in children and adolescents from a public health perspective. We searched the Cochrane COVID-19 Study Register and WHO COVID-19 Global literature on coronavirus disease database on 5 November 2021 and tracked ongoing studies published after this date. We included observational studies on children and adolescents with a follow-up greater than 12 weeks and focused on the outcomes of quality of life, recovery/duration of symptoms, school attendance and resource use/rehabilitation. We assessed their methodological quality, and we prepared a narrative synthesis of the results. We included 21 longitudinal and 4 cross-sectional studies (6 with a control group) with over 68 thousand unvaccinated children and adolescents with mostly asymptomatic or mild disease. Study limitations included convenience sampling, a poor description of their study population and heterogeneous definitions of outcomes. Quality of life was not largely affected in adolescents following COVID-19, but there might be greater impairment in young children and in those with more severe forms of the disease (4 studies). There might also be an impairment in daily activities and increased school absenteeism following COVID-19, but the findings were heterogeneous (5 studies). A total of 22 studies provided highly variable estimates based on heterogeneous definitions of overall persistence of symptoms (recovery), ranging from 0 to 67% at 8–12 weeks and 8 to 51% at 6–12 months. We found limited data on resource use and the need for rehabilitation. One controlled study indicated that the quality of life of infected children and adolescents might not substantially differ from controls. All controlled studies found a higher burden of persistent symptoms in COVID-19 cases compared with test-negative controls or cases of influenza. There is limited evidence on the short and long-term well-being of children following SARS-CoV-2 infection. High-quality longitudinal studies with control groups are needed to describe the outcomes in this population, especially in vaccinated children and those affected by new variants of the virus.
- 3 November 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (21) , 14392
Open AccessShort and Long-Term Wellbeing of Children following SARS-CoV-2 Infection: A Systematic Review
Post-COVID conditions in children and adolescents were mostly investigated as the incidence of individual or clusters of symptoms. We aimed to describe the findings of studies assessing key outcomes related to global wellbeing and recovery in children and adolescents from a public health perspective. We searched the Cochrane COVID-19 Study Register and WHO COVID-19 Global literature on coronavirus disease database on 5 November 2021 and tracked ongoing studies published after this date. We included observational studies on children and adolescents with a follow-up greater than 12 weeks and focused on the outcomes of quality of life, recovery/duration of symptoms, school attendance and resource use/rehabilitation. We assessed their methodological quality, and we prepared a narrative synthesis of the results. We included 21 longitudinal and 4 cross-sectional studies (6 with a control group) with over 68 thousand unvaccinated children and adolescents with mostly asymptomatic or mild disease. Study limitations included convenience sampling, a poor description of their study population and heterogeneous definitions of outcomes. Quality of life was not largely affected in adolescents following COVID-19, but there might be greater impairment in young children and in those with more severe forms of the disease (4 studies). There might also be an impairment in daily activities and increased school absenteeism following COVID-19, but the findings were heterogeneous (5 studies). A total of 22 studies provided highly variable estimates based on heterogeneous definitions of overall persistence of symptoms (recovery), ranging from 0 to 67% at 8–12 weeks and 8 to 51% at 6–12 months. We found limited data on resource use and the need for rehabilitation. One controlled study indicated that the quality of life of infected children and adolescents might not substantially differ from controls. All controlled studies found a higher burden of persistent symptoms in COVID-19 cases compared with test-negative controls or cases of influenza. There is limited evidence on the short and long-term well-being of children following SARS-CoV-2 infection. High-quality longitudinal studies with control groups are needed to describe the outcomes in this population, especially in vaccinated children and those affected by new variants of the virus.
- Open Access
- 11 August 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (16) , 9915
Long-Term Health Symptoms and Sequelae Following SARS-CoV-2 Infection: An Evidence Map
Post-COVID-19 conditions, also known as ‘Long-COVID-19’, describe a longer and more complex course of illness than acute COVID-19 with no widely accepted uniform case definition. We aimed to map the available evidence on persistent symptoms and sequelae following SARS-CoV-2 in children and adults. We searched the Cochrane COVID-19 Study Register and the WHO COVID-19 Global literature on coronavirus disease database on 5 November 2021. We included longitudinal and cross-sectional studies and we extracted their characteristics, including the type of core outcomes for post-COVID-19 conditions. We included 565 studies (657 records). Most studies were uncontrolled cohort studies. The median follow-up time was 13 weeks (IQR 9 to 24). Only 72% of studies were conducted in high-income countries, 93% included unvaccinated adults with mild-to-critical disease, only 10% included children and adolescents, and less than 5% included children under the age of five. While most studies focused on health symptoms, including respiratory symptoms (71%), neurological symptoms (57%), fatigue (54%), pain (50%), mental functioning (43%), cardiovascular functioning (40%), and post-exertion symptoms (28%), cognitive function (26%), fewer studies assessed other symptoms such as overall recovery (24%), the need for rehabilitation (18%), health-related quality of life (16%), changes in work/occupation and study (10%), or survival related to long-COVID-19 (4%). There is a need for controlled cohort studies with long-term follow-up and a focus on overall recovery, health-related quality of life, and the ability to perform daily tasks. Studies need to be extended to later phases of the pandemic and countries with low resources.
- 11 August 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (16) , 9915
Open AccessLong-Term Health Symptoms and Sequelae Following SARS-CoV-2 Infection: An Evidence Map
Post-COVID-19 conditions, also known as ‘Long-COVID-19’, describe a longer and more complex course of illness than acute COVID-19 with no widely accepted uniform case definition. We aimed to map the available evidence on persistent symptoms and sequelae following SARS-CoV-2 in children and adults. We searched the Cochrane COVID-19 Study Register and the WHO COVID-19 Global literature on coronavirus disease database on 5 November 2021. We included longitudinal and cross-sectional studies and we extracted their characteristics, including the type of core outcomes for post-COVID-19 conditions. We included 565 studies (657 records). Most studies were uncontrolled cohort studies. The median follow-up time was 13 weeks (IQR 9 to 24). Only 72% of studies were conducted in high-income countries, 93% included unvaccinated adults with mild-to-critical disease, only 10% included children and adolescents, and less than 5% included children under the age of five. While most studies focused on health symptoms, including respiratory symptoms (71%), neurological symptoms (57%), fatigue (54%), pain (50%), mental functioning (43%), cardiovascular functioning (40%), and post-exertion symptoms (28%), cognitive function (26%), fewer studies assessed other symptoms such as overall recovery (24%), the need for rehabilitation (18%), health-related quality of life (16%), changes in work/occupation and study (10%), or survival related to long-COVID-19 (4%). There is a need for controlled cohort studies with long-term follow-up and a focus on overall recovery, health-related quality of life, and the ability to perform daily tasks. Studies need to be extended to later phases of the pandemic and countries with low resources.
- Open Access
- 1 January 2021
- Published by XMLink in Investigative and Clinical Urology
- Vol. 62 (5) , 520-534
Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement: A systematic review and meta-analysis
Trivisonno LF, et al. Investig Clin Urol. 2021 Sep;62(5):520-534. https://doi.org/10.4111/icu.20210254
- 1 January 2021
- Published by XMLink in Investigative and Clinical Urology
- Vol. 62 (5) , 520-534
Open AccessSerenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement: A systematic review and meta-analysis
Trivisonno LF, et al. Investig Clin Urol. 2021 Sep;62(5):520-534. https://doi.org/10.4111/icu.20210254